Saturday, November 21, 2026

Less Than Hour Before The Market Open, Viking Therapeutics Is Up By 14%

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Less Than  Hour Before The Market Open, Viking Therapeutics Is Up By 14%

(VIANEWS) - The NASDAQ opens in less than hour and Viking Therapeutics's pre-market value is already 14.54% up.

Viking Therapeutics's last close was $69.19, 30.4% under its 52-week high of $99.41.

The last session, NASDAQ finished with Viking Therapeutics (VKTX) dropping 0.52% to $69.19. NASDAQ slid 0.27% to $16,384.47, following the last session's downward trend on what was a somewhat bearish trend exchanging session.

About Viking Therapeutics

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Earnings Per Share

As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.91.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -34.79%.

Growth Estimates Quarters

The company's growth estimates for the current quarter and the next is a negative 12% and a negative 47.4%, respectively.

More news about Viking Therapeutics (VKTX).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 26 Mar 2024
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.